Implantable Defibrillator User, Sudden Cardiac Death
Conditions
Keywords
outcomes, appropriate shock, complications, subcutaneous
Brief summary
Implantable cardioverter-defibrillators have been proven to be effective in the prevention of sudden cardiac death in high-risk patients. However, it is well acknowledged that such a strategy could be optimised, especially through new technologies/devices. Data on the entirely sub-cutaneous implantable cardioverter defibrillator (S-ICD) published so far come from high-volume centers and/or selected populations. The HONEST Cohort -taking the opportunity of a unique scenario with a single manufacturer and remote monitoring system available- aims to collect retrospectively baseline information as well as follow-up of all patients implanted with an S-ICD in France since the first implant in October 13, 2012 until December 31, 2019. An extended prospective yearly follow-up will be carried out since January 1, 2020 until December 31, 2024.
Interventions
Implantation of an S-ICD
Sponsors
Study design
Eligibility
Inclusion criteria
* All patients who require S-ICD implantation (new or battery replacement)
Exclusion criteria
* Refusal of consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ventricular Arrhythmias | Through study completion, an average of 5 years | Rate of appropriate ICD therapies for ventricular tachycardia / fibrillation |
| Device-Related Complications | Through study completion, an average of 5 years | Rate of complications related to ICD including inappropriate therapies, infection, lead or generator dysfunction |
| Overall and Specific Mortalities | Through study completion, an average of 5 years | Overall mortality and causes of death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Early Device-Related Complications | 3 months | Complications occurring within the 3 months following implantation |
| Late Device-Related Complications | Through study completion, an average of 5 year | Complications occurring after 3 months following implantation |
| Stratified Analyses by Sex, Underlying Heart Disease | Through study completion, an average of 5 year | Primary and secondary outcomes studied by sex and types of heart diseases |
Countries
France